Zhou Yifan, Huang Qiao, Lu Tingting, Sun Xiaobo, Fang Ling, Lu Zhengqi, Hu Xueqiang, Kermode Allan, Qiu Wei
Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Department of Neurology, Zhaoqing No. 2 People's Hospital, Guangdong, China.
J Clin Neurosci. 2017 Apr;38:71-73. doi: 10.1016/j.jocn.2016.12.022. Epub 2017 Jan 19.
There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.
目前缺乏治疗儿童多发性硬化症（PedMS）的证据。尚未有使用硫唑嘌呤治疗PedMS的报道。一名10岁的多发性硬化症男孩，其抗髓鞘少突胶质细胞糖蛋白（MOG）-IgG抗体呈血清阳性，接受了硫唑嘌呤加口服甲基泼尼松龙治疗。该患者表现出临床和磁共振成像稳定，且MOG-IgG血清转化。在5年期间未出现重大副作用。对于MOG-IgG血清阳性的儿童多发性硬化症患者，硫唑嘌呤可能是一种治疗选择，特别是在医疗资源匮乏地区。
